BPC-157 + TB-500 dosage chart

20 mg Blend

The BPC-157 + TB-500 peptide blend is dosed at 250 mcg–500 mcg daily via subcutaneous injection in educational protocols. A 20 mg blend reconstituted with bacteriostatic water yields about 6.67 mg/mL. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water → ~6.67 mg/mL total concentration (~3.33 mg/mL of each peptide).
Typical daily range: 250–500 mcg BPC-157 + 250–500 mcg TB-500 (500–1,000 mcg total blend) once daily.
Easy measuring: At 6.67 mg/mL total, 1 unit = 0.01 mL ≈ 66.7 mcg total (~33.3 mcg of each peptide) on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 14 days.
Injection frequency: Once daily — 5 days on, 2 days off (dose Mon–Fri, rest Sat–Sun).
Dosing schedule: 5 days on / 2 days off: dose Monday through Friday, then take Saturday and Sunday off. That is 5 dosing days per week.

Standard / Gradual Approach (3 mL = ~6.67 mg/mL total)

WEEK	DAILY DOSE (TOTAL BLEND)	PER-PEPTIDE DOSE	UNITS (ML)
Weeks 1–2	500 mcg (0.5 mg)	~250 mcg each	7.5 units (0.075 mL)
Weeks 3–4	666 mcg (0.67 mg)	~333 mcg each	10 units (0.10 mL)
Weeks 5–8	1,000 mcg (1.0 mg)	~500 mcg each	15 units (0.15 mL)

Advanced / Loading Phase (Optional)

PHASE	DAILY DOSE (TOTAL BLEND)	PER-PEPTIDE DOSE	UNITS (ML)
Loading (Weeks 1–4)	1,500 mcg (1.5 mg)	~750 mcg each	22.5 units (0.225 mL)
Maintenance (Weeks 5–8)	1,000 mcg (1.0 mg)	~500 mcg each	15 units (0.15 mL)

Reconstitution steps

1Draw 3.0 mL bacteriostatic water with a sterile syringe.
2Inject slowly down the vial wall; avoid foaming or direct stream onto the powder.
3Gently swirl or roll until fully dissolved (do not shake).
4Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Dosing Cycle & Timing

This protocol runs on a 5 days on / 2 days off cycle.

Cycle: 5 days on, 2 days off — dose Monday through Friday and rest on the weekend.
5 dosing days per week; the 2 off days help limit receptor desensitisation and give injection sites time to recover.
Keep the dose time consistent on dosing days.
If a weekday dose is missed, take it the same day if possible — do not dose on an off day to catch up.
Weekly totals in the supplies and shopping lists are calculated on 5 dosing days, not 7.

Protocol Overview

Concise summary of the once-daily regimen.

Goal: Support tissue repair, wound healing, and musculoskeletal recovery in research contexts.
Schedule: Daily subcutaneous injections for 4–8 weeks; some protocols include 3-month-on / 6-week-off cycling.
Dose Range: 500–1,500 mcg total blend daily (providing ~250–750 mcg of each peptide).
Reconstitution: 3.0 mL per 20 mg vial (~6.67 mg/mL total) for accurate unit measurements.
Storage: Lyophilized frozen; reconstituted refrigerated; use within 14 days.

Dosing Protocol

Suggested daily titration approach.

Start: 500–666 mcg total blend daily (~250–333 mcg each peptide).
Target: 1,000 mcg total blend daily (~500 mcg each) by Weeks 3–8.
Frequency: Once per day (subcutaneous).
Cycle Length: 4–8 weeks; optional cycling with 6-week breaks between courses.
Timing: Any consistent time; some prefer morning administration; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality and stability.

Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 14 days and avoid freeze-thaw cycles.
Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

Use new sterile insulin syringes for each injection; dispose properly in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation and maintain absorption.
Inject near the site of injury when targeting localized tissue repair (within anatomical reason).
Document daily dose and site rotation to maintain consistency.
Both BPC-157 and TB-500 are prohibited in competitive sports by WADA.

How This Works

BPC-157 is a synthetic pentadecapeptide (15 amino acids) originally isolated from human gastric juice. Preclinical research indicates it exerts cytoprotective effects across multiple organ systems, promotes angiogenesis, modulates nitric oxide pathways, and interacts with growth-factor systems involved in tissue repair. TB-500 (Thymosin β4) is a naturally occurring peptide that regulates actin polymerization, promotes cell migration, reduces inflammation, and supports wound healing and tissue regeneration. The combination is hypothesized to provide complementary mechanisms for accelerated musculoskeletal and soft-tissue recovery.

Potential Benefits & Side Effects

Observations from preclinical and early clinical literature.

Tissue Repair: Both peptides demonstrate wound-healing, tendon-repair, and anti-inflammatory properties in animal models.
Gastrointestinal Support: BPC-157 shows gastroprotective and ulcer-healing effects in preclinical studies.
Safety Profile: Preclinical data indicate a wide safety margin for BPC-157 (no lethal dose up to ~20 mg/kg); TB-500 human tolerability studies report mild adverse events at doses up to 1,260 mg.
Possible Side Effects: Occasional mild injection-site reactions (redness, itching); rare reports of transient dizziness or nausea; long-term human safety data remain limited.

Lifestyle Factors

Complementary strategies for best outcomes.

Prioritize adequate protein intake to support tissue synthesis and repair.
Combine with appropriate rehabilitation protocols when addressing musculoskeletal injuries.
Ensure quality sleep and stress management to optimize recovery and healing responses.
Stay hydrated and maintain balanced micronutrient intake (vitamins C, D, zinc) to support connective-tissue health.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

Clean the vial stopper and injection site with alcohol; allow to dry completely.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue (use 23–25 gauge, 5/8″ needle).
Aspiration is unnecessary for subcutaneous injections; inject slowly and steadily.
Rotate sites systematically (abdomen, lateral thigh, upper arm, buttocks) to avoid lipohypertrophy.
For localized injuries, inject subcutaneously near (not into) the affected area when anatomically appropriate.

Important Note

This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Both BPC-157 and TB-500 are unapproved investigational peptides. Consult a qualified healthcare professional before considering any research application.

Supplies needed

Plan covers the full 8-week protocol at the lowest listed starting dose: 0.5 mg per dose, 5 days on / 2 days off (40 administrations in total), using 20 mg vials. After mixing with 3 mL, the concentration is 6.67 mg/mL and each dose requires 0.08 mL total.

BPC-157 + TB-500 vials (20 mg Blend each)

Vials are rounded up only after calculating the whole protocol: ceil(20 ÷ 20) = 1. Usable peptide remaining in an opened vial carries forward to the next dose.

Full protocol (8 weeks): 1 vial (20 mg needed ÷ 20 mg)

Insulin syringes (U-100, 1 mL)

One fresh syringe per administration.

Full protocol (8 weeks): 40 syringes

Bacteriostatic water (10 mL bottles)

Use 3 mL per vial for reconstitution (1 × 3 mL = 3 mL).

Full protocol (8 weeks): 1 × 10 mL bottle

Alcohol swabs

One for the vial stopper per draw + one for each injection site (5 days on / 2 days off). Recommend 1 × 100-count box.

Full protocol (8 weeks): 80 swabs

Supply	Full protocol (8 weeks)
BPC-157 + TB-500 vials (20 mg Blend each)Vials are rounded up only after calculating the whole protocol: ceil(20 ÷ 20) = 1. Usable peptide remaining in an opened vial carries forward to the next dose.	1 vial (20 mg needed ÷ 20 mg)
Insulin syringes (U-100, 1 mL)One fresh syringe per administration.	40 syringes
Bacteriostatic water (10 mL bottles)Use 3 mL per vial for reconstitution (1 × 3 mL = 3 mL).	1 × 10 mL bottle
Alcohol swabsOne for the vial stopper per draw + one for each injection site (5 days on / 2 days off). Recommend 1 × 100-count box.	80 swabs

BPC-157 + TB-500 dosage FAQs

How much bacteriostatic water do you use to reconstitute BPC-157 + TB-500?

Add 3.0 mL bacteriostatic water → ~6.67 mg/mL total concentration (~3.33 mg/mL of each peptide). for a 20 mg Blend vial. Add the water slowly against the inside wall of the vial and swirl — never shake — until the powder fully dissolves.

How often is BPC-157 + TB-500 administered in research protocols?

Injection frequency: Once daily — 5 days on, 2 days off (dose Mon–Fri, rest Sat–Sun).

What does the BPC-157 + TB-500 standard / gradual approach (3 ml = ~6.67 mg/ml total) look like?

Weeks 1–2 — 500 mcg (0.5 mg) — ~250 mcg each — 7.5 units (0.075 mL); Weeks 3–4 — 666 mcg (0.67 mg) — ~333 mcg each — 10 units (0.10 mL); Weeks 5–8 — 1,000 mcg (1.0 mg) — ~500 mcg each — 15 units (0.15 mL). The full table above lists every step with matching syringe units.

What are the mixing steps for BPC-157 + TB-500?

Draw 3.0 mL bacteriostatic water with a sterile syringe. Inject slowly down the vial wall; avoid foaming or direct stream onto the powder. Gently swirl or roll until fully dissolved (do not shake).

How should reconstituted BPC-157 + TB-500 be stored?

Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 14 days..

How many insulin syringe units equal a BPC-157 + TB-500 dose?

Units depend on the water volume you used. Divide your target dose by the vial concentration to get millilitres, then multiply by 100 — 1 unit on a U-100 insulin syringe is 0.01 mL. The Spartan Peptides reconstitution calculator does this conversion for you.

Is BPC-157 + TB-500 approved for human use?

No. BPC-157 + TB-500 is sold and referenced strictly as a research chemical. Nothing on this page is medical advice and the material is not for human consumption.

Educational and research information only. Not medical advice, not for human consumption. Values are reference figures — always verify your own math with the reconstitution calculator.

On any insulin syringe, 1 unit = 0.01 mL, so unit counts above hold across brands.